Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Update

Iterum Therapeutics plc (NASDAQ:ITRM) was the target of a large drop in short interest in September. As of September 30th, there was short interest totalling 215,300 shares, a drop of 37.0% from the September 15th total of 341,700 shares. Based on an average daily trading volume, of 314,300 shares, the short-interest ratio is currently 0.7 days. Currently, 1.0% of the shares of the stock are short sold.

Iterum Therapeutics Trading Up 8.6 %

Shares of Iterum Therapeutics stock traded up $0.08 during trading on Monday, hitting $1.01. 374,285 shares of the stock traded hands, compared to its average volume of 344,806. The stock’s fifty day simple moving average is $1.11 and its 200 day simple moving average is $1.29. The firm has a market cap of $16.72 million, a P/E ratio of -0.40 and a beta of 2.26. Iterum Therapeutics has a 52-week low of $0.62 and a 52-week high of $2.50.

Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.22. As a group, equities analysts expect that Iterum Therapeutics will post -1.19 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Iterum Therapeutics in a report on Tuesday, September 10th.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.